Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155749 · ClinicalTrials.gov registry record · Phase 1
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
A Phase 1 study of Relapsed and Refractory Multiple Myeloma, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT04155749 is a Phase 1 study of Relapsed and Refractory Multiple Myeloma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 40 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT04155749, a Phase 1 study of Relapsed and Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Conditions Studied
Interventions
- DRUG anitocabtagene-autoleucel
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Illinois
- Advanced Cellular Therapeutics Facility, DCAM 0800A - Chicago
Wisconsin
- Froedtert Hospital/Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155749
The ClinicalTrials.gov registry entry for NCT04155749 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed and Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which anitocabtagene-autoleucel is the first listed.
NCT04155749 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04155749 about?
NCT04155749 is a clinical study titled "Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma". Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
What is the current status of trial NCT04155749?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-12-23. Estimated completion is 2027-05.
What conditions does trial NCT04155749 study?
This clinical trial studies the following conditions: Relapsed and Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04155749?
The interventions under investigation include: anitocabtagene-autoleucel (DRUG).
Who is sponsoring clinical trial NCT04155749?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155749 being conducted?
This trial has 4 study locations across Illinois, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed and Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.